AccuStem Sciences employs biomarker analysis to provide precise insights into tumor biology, enabling the development of personalized treatment plans for cancer patients. This approach directly addresses the issue of ineffective therapies, leading to improved patient outcomes through tailored interventions.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for determining cancer treatment plans often lack precise insights into the unique biology of individual tumors. This can lead to the use of ineffective therapies, resulting in suboptimal patient outcomes and reduced quality of life. There is a need for more accurate and personalized diagnostic tools to guide treatment decisions.
Solution
AccuStem Sciences is developing a suite of novel genomic tests designed to provide a more integrated solution for physicians and their patients across the entire continuum of oncology care, from screening to treatment and monitoring. Their approach focuses on interrogating novel disease pathways, such as tumor "stemness," to provide a deeper understanding of the biology of each patient's cancer. AccuStem's lead product, StemPrintER, is a proprietary 20-gene test that stratifies breast cancer patients according to their risk of recurrence by measuring the "stemness" of tumors. StemPrintER has demonstrated superior performance compared to existing market-leading tests in identifying patients at high risk of recurrence.
Target Audience
AccuStem's primary customers are physicians, oncologists, and care teams involved in cancer screening, treatment planning, and monitoring, as well as hospital and private pathology laboratories.
Features
- Proprietary 20-gene assay to measure tumor "stemness"
- Risk stratification of early-stage breast cancer patients
- Identification of patients likely to experience distant recurrence
- Superior performance compared to OncotypeDX in clinical trials (transATAC study)
- Potential to determine the most effective surgical approach for early-stage invasive breast cancer
- Development of additional proprietary cancer assays leveraging StemPrintER technology